National Pension Service increased its holdings in shares of Medtronic PLC (NYSE:MDT – Free Report) by 1.0% in the 4th quarter, HoldingsChannel.com reports. The firm owned 2,982,411 shares of the medical technology company’s stock after acquiring an additional 28,269 shares during the period. National Pension Service’s holdings in Medtronic were worth $286,490,000 as of its most recent SEC filing.
Several other large investors have also added to or reduced their stakes in MDT. Lodestone Wealth Management LLC acquired a new position in Medtronic during the fourth quarter worth $27,000. Anfield Capital Management LLC increased its position in shares of Medtronic by 410.7% during the 4th quarter. Anfield Capital Management LLC now owns 286 shares of the medical technology company’s stock worth $27,000 after purchasing an additional 230 shares during the last quarter. Valley Wealth Managers Inc. acquired a new position in shares of Medtronic during the 3rd quarter worth approximately $29,000. Board of the Pension Protection Fund acquired a new position in shares of Medtronic during the 4th quarter worth approximately $29,000. Finally, GoalVest Advisory LLC acquired a new position in shares of Medtronic during the 4th quarter worth approximately $29,000. Institutional investors and hedge funds own 82.06% of the company’s stock.
Analysts Set New Price Targets
MDT has been the topic of several recent analyst reports. Leerink Partners reaffirmed an “outperform” rating and set a $119.00 price target on shares of Medtronic in a research report on Tuesday, March 10th. JPMorgan Chase & Co. cut their price target on shares of Medtronic from $105.00 to $100.00 and set a “neutral” rating for the company in a research note on Wednesday, February 18th. Weiss Ratings cut shares of Medtronic from a “hold (c+)” rating to a “hold (c)” rating in a research note on Thursday, May 21st. Stifel Nicolaus cut their price target on shares of Medtronic from $105.00 to $95.00 and set a “hold” rating for the company in a research note on Monday, April 6th. Finally, Wells Fargo & Company started coverage on shares of Medtronic in a research note on Friday, January 30th. They issued an “overweight” rating and a $114.00 price target for the company. Fifteen analysts have rated the stock with a Buy rating and eleven have issued a Hold rating to the stock. According to MarketBeat, the company presently has an average rating of “Moderate Buy” and an average target price of $106.45.
Key Headlines Impacting Medtronic
Here are the key news stories impacting Medtronic this week:
- Positive Sentiment: Medtronic’s Evolut TAVR platform was highlighted for superior clinical outcomes, which could support the company’s competitive position in a market expected to grow from $7.0 billion in 2025 to $13.8 billion by 2035. Medtronic’s Evolut displays superior clinical outcomes
- Positive Sentiment: Some commentary suggests Medtronic may be trading closer to fair value after its recent pullback, with M&A activity, FDA clearances, and product strength providing longer-term upside potential. Medtronic’s Fair Value Falls Between Caution And Optimism
- Neutral Sentiment: Analysts continue to frame Medtronic as a mixed story into earnings, with some seeing the stock as fairly valued after its decline and others watching whether acquisitions and new product approvals can offset slower growth. Can Medtronic (MDT) Close the Growth Gap With Its Bigger MedTech Rivals?
- Neutral Sentiment: Medtronic is scheduled to report earnings on June 3, and coverage ahead of the release has focused on expectations for a earnings decline, which is keeping sentiment cautious. Analysts Estimate Medtronic (MDT) to Report a Decline in Earnings: What to Look Out for
- Negative Sentiment: Investor sentiment remains pressured ahead of earnings, with the stock recently down over short time frames and a voluntary Class II software recall adding another near-term headwind. Medtronic (MDT) Valuation Check As Earnings Approach And M&A FDA Moves And Recall Shape Sentiment
- Negative Sentiment: Recent trading showed Medtronic slipping despite a broader market advance, reinforcing the view that investors are rotating out of the name until the earnings update provides more clarity. Medtronic (MDT) Stock Drops Despite Market Gains: Important Facts to Note
Medtronic Stock Performance
Shares of MDT stock opened at $75.56 on Friday. The stock has a market cap of $97.01 billion, a P/E ratio of 21.05, a P/E/G ratio of 1.81 and a beta of 0.62. The company has a debt-to-equity ratio of 0.57, a current ratio of 2.54 and a quick ratio of 1.87. The company has a fifty day moving average price of $82.63 and a two-hundred day moving average price of $92.78. Medtronic PLC has a one year low of $74.40 and a one year high of $106.33.
Medtronic Dividend Announcement
The company also recently declared a quarterly dividend, which was paid on Friday, April 17th. Shareholders of record on Friday, March 27th were paid a $0.71 dividend. The ex-dividend date was Friday, March 27th. This represents a $2.84 dividend on an annualized basis and a yield of 3.8%. Medtronic’s dividend payout ratio (DPR) is currently 79.11%.
Medtronic Profile
Medtronic plc is a global medical technology company that develops and manufactures a broad range of therapeutic devices and health care solutions. Headquartered legally in Ireland with principal operational offices in the United States, the company markets products to hospitals, physicians and health systems worldwide and has grown from its founding in 1949 into one of the largest medical-device manufacturers serving global health-care markets.
Medtronic’s offerings span several clinical areas, including cardiac rhythm and heart failure (pacemakers, implantable cardioverter‑defibrillators and related cardiac therapies), minimally invasive and surgical technologies (laparoscopic and advanced energy devices, visualization systems and surgical innovations), restorative therapies (spine and orthopedics, neuromodulation and neurovascular treatments) and diabetes management (insulin-delivery systems and glucose monitoring solutions).
Read More
- Five stocks we like better than Medtronic
- 3 Stocks Rallying on Micron’s Price Boost: Substance or Hype?
- Snowflake and the Snowballing Impact of its AI Flywheel
- AI’s Biggest Bottleneck Could Make These 2 Stocks Soar
- These 3 Beaten-Down Stocks Just Saw $25 Million in Insider Buying
Want to see what other hedge funds are holding MDT? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Medtronic PLC (NYSE:MDT – Free Report).
Receive News & Ratings for Medtronic Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Medtronic and related companies with MarketBeat.com's FREE daily email newsletter.
